People

The People

Governance grade: C-. A controlling shareholder (Gold Sino) is on track to own 49% via a string of related-party private placements at discounted prices, the director who chairs the Nominating committee is the same person personally pledging to procure that equity, and three of the four non-executive directors are linked to the same Ruentex / Nan Shan complex. The audit committee approved the deals and pay is modest, but minority shareholders are now plainly along for the ride.

The People Running This Company

Gogoro is a post-founder company: visionary CEO Horace Luke exited in September 2024 and was replaced by Henry Chiang, a 33-year-old operator promoted from running Gogoro Taiwan. Decision-making power is concentrated in CFO Bruce Aitken (the only executive with seven-plus years of tenure) and Chairman Tamon Tseng, the Ruentex Group's longtime general counsel.

The two members worth the most scrutiny:

• Henry Chiang (CEO). Domestic operator who scaled GoShare and ran Taiwan retail. Has no equity stake to speak of and was 32 years old when promoted to interim CEO. Reasonable for stabilizing the core business; an unproven choice for capital markets, international expansion, and crisis negotiation with lenders and the controlling shareholder.
• Chung-Yao Yin (Director, NomGov Chair). Chairman of Nan Shan Life Insurance, member of the Ruentex family enterprise, and the operative link to Gold Sino. He is the director the lenders required to personally underwrite the NT$2.5 billion equity commitment. The board has formally designated him "independent" under Nasdaq rules; in substance he is the controlling shareholder's representative.

Chairman Tamon Tseng was installed at the same moment the founder left — and he comes from the same Ruentex orbit as Yin. The Chairman/CEO split is real on paper, but the chair, the audit chair predecessor's replacement dynamics, the NomGov chair, and the controlling shareholder all sit inside one Taiwanese conglomerate ecosystem.

What They Get Paid

Aggregate compensation for all executive officers and directors in FY2025 was approximately $1.2 million in cash, with zero share-based awards granted in 2025. That is a sharp reset from the SPAC-era equity issuance and is the single most shareholder-friendly governance signal in this report.

For a NASDAQ-listed company with ~1,300 employees and $281M of revenue, $1.2M of aggregate cash compensation across the CEO, CFO, Chairman, and three other directors is modest by any peer standard. The 2024 share grants for CEO and CFO were struck at $25.80 (post-consolidation) — well below where the stock has since traded — but quantity disclosed only as "less than 1%" each, so the dollar value is not material. The 2022 grants at $104.00 and 2023 grants at $60.20 are deeply out of the money and effectively worthless.

Bottom line: Pay is unusually low and not a source of governance risk. The risk lies entirely in how new equity gets issued to outsiders, not in how it is awarded to insiders.

Are They Aligned?

This is where the case turns. Management has almost no skin in the game, and the company is being recapitalized by a single controlling shareholder at successively favorable terms.

Ownership map

Excluding Yin's Gold Sino-linked 3.3%, executive insiders own well under 1% combined. CEO Chiang, CFO Aitken, and audit chair Cheng are each listed as * (<1%). There is no founder block remaining: Horace Luke is gone and is not on the cap table in any disclosed capacity. Castrol's 5.7% stake comes with a put option requiring Gogoro to repurchase shares at original price under change-of-control, delisting, or unsatisfied JV conditions — i.e. not a true long-term aligned holder either.

Insider buying vs selling

There are no disclosed open-market insider purchases or sales by Chiang, Aitken, Tseng, Cheng, or Chang. Every dollar of "insider" capital flow is Gold Sino subscribing to new shares at a negotiated discount. That is one-sided: it lowers the per-share entry price for the controlling holder, dilutes minorities, and is structured (March 2026 SPA at $3.15, a 10% discount to 30-day VWAP) so that the controlling stake creeps toward 50%.

Dilution

Share count grows from 11.1M at IPO (2022) to 14.8M at year-end 2025, and to 20.1M pro-forma after the March 2026 Gold Sino SPA closes — a ~36% one-quarter increase off the YE2025 share base (and roughly +52% if measured against the YE2024 base of 13.25M before the FY2025 issuances). The October 2025 1-for-20 reverse split was used to restore Nasdaq bid-price compliance, not to return capital. Together with Castrol's outstanding put right and Gold Sino's still-live warrant, further dilution is on the table.

Related-party behavior

Two structural problems:

1. The director procuring the equity is the affiliate of the buyer. The Mega Bank lenders required someone to underwrite future equity to relax covenants. The board chose Yin, who is also affiliated with Gold Sino. Gold Sino is now executing the undertaking by buying the new shares itself, at discounts it negotiates with the board on which Yin sits.
2. The audit committee approved the SPA, but the approving committee is structurally narrow. Only two directors sit on the audit committee (HM Cheng, Karen Chang). Karen Chang joined only in May 2025. HM Cheng has been on the board since 2013 — long enough to be aligned with the prior ownership structure that Ruentex/Gold Sino is now displacing.

Capital allocation

Capital allocation in 2025 is the strongest positive: capex cut nearly in half to $65M (from $124M in 2024), operating cash flow up to $35.9M, no buybacks (appropriate given the cash position), no dividends. Total debt of $456M against $70.6M of cash still constrains everything, and $151.9M of that debt is current. The company would not be a going concern without Yin's personal undertaking.

Skin-in-the-game score: 3 / 10

Management itself has effectively no equity stake; the only large insider position belongs to the controlling shareholder's affiliate. Pay is modest and SBC has collapsed — both positives — but alignment with public minorities is weak because the controlling shareholder is acquiring the company on the installment plan at discounted prices.

Board Quality

The board declares three of six directors (Cheng, Yin, Chang) "independent" under Nasdaq rules. In substance:

• Karen Yifen Chang is the only director with no Ruentex/Gold Sino linkage and no founder-era continuity. She also sits on all three committees — appropriate, but it means independent challenge depends on a single person who only joined in May 2025.
• Hui-Ming Cheng is financially expert and chairs both audit and compensation. With 13 years of board tenure he should rotate; ISS would not consider him independent indefinitely.
• Chung-Yao Yin chairs the Nominating & Corporate Governance Committee, which is uncomfortable given his Gold Sino affiliation and his personal undertaking to procure equity. The director responsible for board composition is also the controlling-shareholder representative.

Other observations worth noting:

• Staggered board (three classes, three-year terms): entrenchment risk, makes any future activist or proxy challenge multi-year.
• No standing risk committee; risk oversight done by the whole board, fine given the size.
• No restatements and no clawback events in 2025; the August 2023 clawback policy is on file.
• Board size dropped during the transition (a director departed when Karen Chang was added in May 2025), and the disclosed FY2025 director count is small relative to peers — fewer eyes on management.

The Verdict

Governance grade: C-.

Strongest positives. Pay is genuinely modest, SBC fell more than 95% from 2022 to 2025, the clawback policy is in place, capital allocation discipline appeared in 2025 (capex cut, OCF up), and CFO Aitken provides real continuity at the operational seam. The audit committee did formally approve the related-party SPA.

Real concerns. Gold Sino is acquiring control on the installment plan at negotiated discounts; the director procuring that capital is the same controlling-shareholder affiliate; only one director (Karen Chang, 12 months tenured) is substantively independent; the CEO is 32-when-appointed with no equity stake; the company would not have remained a going concern without the director-level undertaking to a Taiwanese bank. Management itself has nothing meaningful at risk.

What would move the grade.

• Upgrade to B- if (a) a second substantively independent director is added with no Ruentex/Nan Shan linkage, (b) Gold Sino's stake is capped or its accumulation paused after the 49% subscription, and (c) the audit committee discloses the third-party fairness opinion behind the 10% VWAP discount.
• Downgrade to D if (a) Gold Sino crosses 50% without a coattail provision for minorities, (b) Castrol exercises its put and is repurchased while public shareholders are not, or (c) any additional discounted PIPE is executed without independent committee approval beyond Cheng + Chang.